Eli Lilly's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Eli Lilly (LLY) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Eli Lilly vs Its Competitors
- TTM: Trailing 12-month revenue of 79,666M vs 591,026M combined for tracked competitors (11.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+15.4% annualized vs trailing 12 months), vs accelerating (+2.2%) for its tracked peer group.
- Growth: Eli Lilly generated 47.7% revenue growth year over year in Q2 2026, vs 6.6% for its tracked competitors combined.
- Profitability: Its 30.9% net margin compares with 4.8% for the peer group.
- Scale: Eli Lilly ranks #1 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 19.3% of industry market cap.
- Peer revenue share: Eli Lilly accounted for 13.2% of combined revenue among its tracked peer group, up from 9.9% a year earlier.
- Peer differentiation: Revenue per employee of $1.59M compares with $0.91M for the peer group (1.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LLY Sales vs. its Competitors, Q2 2026
Eli Lilly reported revenue growth of 47.67 % year on year in Q2 2026, above its competitors' combined revenue growth of 6.57 %.
With a net margin of 30.88 %, Eli Lilly achieved higher profitability than its competitors (4.75 %).
Eli Lilly generated 13.21 % of the combined sales of its peer group, up from 9.90 % a year earlier.
Eli Lilly vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Eli Lilly and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Eli Lilly And Company | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (46) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Eli Lilly's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 47.7% for Eli Lilly. Eli Lilly's share of combined industry revenue moved from 2.17% to 2.98%, a gain of 0.82 percentage points.
Eli Lilly's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Eli Lilly And Company | Yes | Yes | Yes | No |
| Competitors combined (194) | ||||
| High-Confidence Competitors (71) | ||||
| Similar-Size Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LLY Stock Performance relative to its Competitors
LLY Stock Performance relative to High-Confidence Competitors
LLY Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Climb Bio Inc | 282.9% | Outperformed |
| 4 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 5 | Damora Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Eli Lilly's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Eli Lilly's Comment on Competition and Industry Peers
Our human pharmaceutical products compete globally with products of many other
companies in highly competitive markets. Our animal health products compete
globally with products of animal health care companies as well as pharmaceutical,
chemical, and other companies that operate animal health businesses.
Important competitive factors for both human pharmaceutical and animal health
products include effectiveness, safety, and ease of use; price and demonstrated
cost-effectiveness; marketing effectiveness; and research and development of
new products and processes. Most new products that we introduce must compete
with other branded or generic products already on the market or products that
are later developed by competitors. If competitors introduce new products or
delivery systems with therapeutic or cost advantages, our products can be subject
to decreased sales, progressive price reductions, or both.
We believe our long-term competitive success depends upon discovering and developing
(either alone or in collaboration with others) or acquiring innovative, cost-effective
human pharmaceutical and animal health products that provide improved outcomes
and deliver value to payers, together with our ability to continuously improve
the productivity of our operations in a highly competitive environment. There
can be no assurance that our research and development efforts will result in
commercially successful products, and it is possible that our products will
become uncompetitive from time to time as a result of products developed by
our competitors.
Generic Pharmaceuticals
One of the biggest competitive challenges we face is from generic pharmaceuticals.
In the U.S. and the EU, the regulatory approval process for human pharmaceuticals
(other than biological products (biologics)) exempts generics from costly and
time-consuming clinical trials to demonstrate their safety and efficacy, allowing
generic manufacturers to rely on the safety and efficacy of the innovator product.
Therefore, generic manufacturers generally invest far less than we do in research
and development and can price their products much lower than our branded products.
Accordingly, when a branded non-biologic human pharmaceutical loses its market
exclusivity, it normally faces intense price competition from generic forms
of the product. In many countries outside the U.S., intellectual property protection
is weak and we must compete with generic or counterfeit versions of our products.
Many of our animal health products also compete with generics.
Publicly Traded Peers of Eli Lilly And Company
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Procter and Gamble Co | 361,061.51 | 87,032.00 |
| SUBTOTAL | 5,831,515.97 | 984,398.82 |
Sign in to see all competitors of Eli Lilly And Company.
Sources: Eli Lilly And Company's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Eli Lilly And Company versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Eli Lilly's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Petvivo Holdings Inc | Named by the company | 85% |
| Acumen Pharmaceuticals Inc | Named by the company | 85% |
| Regencell Bioscience Holdings Limited | Named by the company | 85% |
| Agentix Corp | Named by the company | 85% |
| Mangoceuticals Inc | Named by the company | 85% |
| Fibrobiologics Inc | Named by the company | 85% |
| Monopar Therapeutics Inc | Named by the company | 85% |
| Intensity Therapeutics Inc | Named by the company | 85% |
| Sagimet Biosciences inc | Named by the company | 85% |
| Novo Nordisk A | Named by the company | 85% |
| Curanex Pharmaceuticals Inc | Named by the company | 85% |
| Elicio Therapeutics Inc | Named by the company | 85% |
| Halozyme Therapeutics Inc | Named by the company | 85% |
| Sab Biotherapeutics Inc | Named by the company | 85% |
| Innate Pharma Sa | Named by the company | 85% |
| Akero Therapeutics Inc | Named by the company | 85% |
| Vaxxinity Inc | Named by the company | 85% |
| Lumos Pharma Inc | Named by the company | 85% |
| Bicara Therapeutics Inc | Named by the company | 85% |
| Exagen Inc | Named by the company | 85% |
| MNMD | Named by the company | 85% |
| Can fite Biopharma Ltd | Named by the company | 85% |
| Neurosense Therapeutics Ltd | Named by the company | 85% |
| Contineum Therapeutics Inc | Named by the company | 85% |
| Beone Medicines Ltd | Named by the company | 85% |
| Denali Therapeutics Inc | Named by the company | 85% |
| Immunome Inc | Named by the company | 85% |
| Aclaris Therapeutics Inc | Named by the company | 85% |
| Skye Bioscience Inc | Named by the company | 85% |
| Invivyd Inc | Named by the company | 85% |
| Altimmune inc | Named by the company | 85% |
| Voyager Therapeutics Inc | Named by the company | 85% |
| Biorestorative Therapies Inc | Named by the company | 85% |
| Mirati Therapeutics Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Nyxoah Sa | Named by the company | 85% |
| Cytokinetics Incorporated | Named by the company | 85% |
| Protagonist Therapeutics inc | Named by the company | 85% |
| Inflarx N V | Named by the company | 85% |
| Abvc Biopharma Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Eli Lilly's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Eli Lilly's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Procter and Gamble Co | Fabric & Home Care 34.83 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Procter and Gamble Co | 361,062 | 836,846 | 155,231 |
| PEERS TOTAL | 4,772,678 | 914,062 | 123,218 |
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Procter and Gamble Co | Non-US 52.05 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Eli Lilly's industry classification, broader than the peer set above. Market cap in millions of $.Eli Lilly ranks #1 of 498 companies by market capitalization in its industry, holding 19.26 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 19.26 % |
| 2 | Johnson and Johnson | 663,585 | 12.07 % |
| 3 | Beone Medicines Ltd | 552,468 | 10.05 % |
| 4 | Abbvie Inc | 471,582 | 8.58 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Eli Lilly's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Eli Lilly's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 66.38 % |
| 2 | Johnson and Johnson | 663,585 | 53.25 % |
| 3 | Beone Medicines Ltd | 1,234 | 12.3% |
| 4 | Abbvie Inc | 1,234 | 12.3% |
| 5 | Merck and Co Inc | 1,234 | 12.3% |
| 6 | Novartis Ag | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Eli Lilly's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Eli Lilly's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 83.40 % | 64.89 % (avg) | +18.5 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 44.80 % | -7.21 % (avg) | +52.0 pp |
| Capital Intensity (Capex / Revenue) | 12.42 % | 4.92 % (avg) | +7.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Eli Lilly's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 37.4x | 25.1x | +12.3x |
| EV / EBITDA | 29.0x | 17.3x | +11.7x |
| P/B | 34.5x | 4.5x | +30.0x |
| Return on Equity | 92.54 % | industry aggregate | 75.29 % |
| Return on Invested Capital | - | -2.95 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Eli Lilly's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 10.41 % | -11.62 % | 9.95 % | 15.40 % | 0.79 % | 19.56 % | 32.00 % | 44.70 % |
| Operating Margin | 12.21 % | 22.29 % | 24.69 % | 22.45 % | 24.97 % | 30.06 % | 35.92 % | 44.82 % |
| Return on Invested Capital | 6.79 % | 16.57 % | 16.88 % | 15.16 % | 17.27 % | 22.45 % | 27.23 % | 33.80 % |
| P/E | 48.6x | 14.4x | 24.2x | 42.0x | 52.1x | 103.7x | 67.0x | 45.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Eli Lilly's BCG Growth-Share Matrix
Relative market share (vs Eli Lilly's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Eli Lilly falls in the Cash Cow quadrant: relative market share of 1.60x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Eli Lilly's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 823 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 12.42 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Eli Lilly's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Eli Lilly's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Eli Lilly's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Eli Lilly falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Eli Lilly's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Market leader by capitalization in its industry (#1 of 498, 19.26 % share).
- Return on equity 75.3 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+15.4% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (39.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Eli Lilly's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Procter and Gamble Co | 0.25 | 0.71 | 0.71 |
Sign in to see all peers for Eli Lilly And Company.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Eli Lilly's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Procter and Gamble Co | Q2 2026 | +1.5 % | -15.0 % |
| PEERS TOTAL | +9.4 % | -4.7 % |
Sign in to see all peers for Eli Lilly And Company.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Eli Lilly's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Procter and Gamble Co | Q2 2026 | +2.7 % | +2.7 % |
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Procter and Gamble Co | 12.72% | 17.81% | 30.05% |
Sign in to see all peers for Eli Lilly And Company.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Eli Lilly's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 31.48 | 6.78 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Abbvie Inc | 75.22 | 7.32 |
| Merck and Co Inc | 119.91 | 5.52 |
| Procter and Gamble Co | 22.62 | 4.15 |
| PEERS AVERAGE | 39.22 | 5.92 |
Sign in to see all peers for Eli Lilly And Company.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.